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Abstract
The serine/threonine kinase LKB1 is a tumour suppressor that regulates multiple biological pathways, including cell cycle
control, cell polarity and energy metabolism by direct phosphorylation of 14 different AMP-activated protein kinase (AMPK)
family members. Although many downstream targets have been described, the regulation of LKB1 gene expression is still
poorly understood. In this study, we performed a functional analysis of the human LKB1 upstream regulatory region. We
used 200 base pair deletion constructs of the 59-flanking region fused to a luciferase reporter to identify the core promoter.
It encompasses nucleotides 2345 to +52 relative to the transcription start site and coincides with a DNase I hypersensitive
site. Based on extensive deletion and substitution mutant analysis of the LKB1 promoter, we identified four cis-acting
elements which are critical for transcriptional activation. Using electrophoretic mobility shift assays as well as chromatin
immunoprecipitations, we demonstrate that the transcription factors Sp1, NF-Y and two forkhead box O (FOXO) family
members FOXO3 and FOXO4 bind to these elements. Overexpression of these factors significantly increased the LKB1
promoter activity. Conversely, small interfering RNAs directed against NF-Y alpha and the two FOXO proteins greatly
reduced endogenous LKB1 expression and phosphorylation of LKB1’s main substrate AMPK in three different cell lines.
Taken together, these results demonstrate that Sp1, NF-Y and FOXO transcription factors are involved in the regulation of
LKB1 transcription.
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Introduction
Liver Kinase B1 (LKB1, also called STK11) was initially
identified as the tumour suppressor gene mutated in the inherited
Peutz-Jeghers cancer syndrome, an autosomal dominant genetic
disorder [1,2,3,4]. It encodes a ubiquitously expressed and
evolutionary well conserved protein kinase that is also inactivated
in a large percentage of sporadic lung and cervical carcinomas
[5,6,7,8]. Indeed, examining the HPV18-positive cervical carci-
noma cell line HeLa, LKB1 is not transcribed. Transcription,
however, can be reconstituted by trans complementation [9] after
somatic cell hybridization with normal human fibroblasts, leading
to cellular hybrids with a non-tumourigenic phenotype. Tumouri-
genic segregants derived from the same hybrids again have lost
LKB1 expression, suggesting that LKB1 down-regulation may
favor progression towards malignancy [6].
Furthermore, LKB1 (+/2) mice develop hepatocellular carcino-
mas after loss of heterozygosity and loss of LKB1 also correlates with
increased metastasis in a well-studied mouse model of lung
carcinogenesis [10]. In this model, LKB1-deficient tumours showed
even more frequent metastasis than tumours lacking the tumour
suppressor p53 [11]. Known mechanisms that explain how LKB1
operates as a tumour suppressor, mainly depend on direct
phosphorylation of different AMP-activated protein kinase (AMPK)
familymembers[12,13,14,15]. AMPKis a multi-component enzyme
complex that acts as metabolic stress-sensor. Once activated, AMPK
switches off many ATP-utilizing processes in order to sustain energy
homeostasis. AMP binding allosterically activates AMPK, facilitating
the binding of upstream kinases that enhance its activity [16].
Although various downstream targets such as the mammalian
target-of-rapamycin (mTOR) pathway have been studied in detail
[14], the regulation of LKB1 gene expression is still poorly
understood. Hence, analysis of the transcriptional regulation of
LKB1 should not only be helpful to identify important trans-acting
regulatory proteins that can alter gene expression, but also to
define critical cis-regulatory regions indispensable for its transcrip-
tional control. Such regions could be affected in a variety of cases
in which LKB1 was inactivated without having mutations within
the coding sequence [17,18]. Here, gene silencing via de novo DNA-
methylation of CpG-rich stretches could be such a scenario [19].
Therefore, identification and characterization of the LKB1
promoter and transcriptional regulators is not only important to
unravel the complexity of LKB1 gene silencing, but also to
understand how upstream regulatory proteins mediate metabolic
sensoring of nutritional depletion and in turn cell cycle control.
In this study we performed a functional analysis of the LKB1
promoter and identified distinct cis-regulatory elements, including
three CCAAT boxes and a non-canonical GC-box that critically
affected LKB1 gene expression. These elements bind NF-Y and
Sp1, representing two ubiquitous transcription factors involved in
the regulation of various genes [20,21]. Furthermore, two
forkhead box O (FOXO) transcription factors that bind the
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LKB1 gene transcription through interaction with their cognate
recognition site 59-GTAAACAA-39 [22]. FOXO transcription
factors become inactivated by certain growth factors [23] through
direct phosphorylation by the protein kinase B (PKB) [24,25].
Since several FOXO target genes are involved in growth control
and cell cycle regulation, their inactivation could represent a
critical event in malignant transformation [26,27]. Therefore, our
findings that functionally link FOXO proteins to the transcrip-
tional activation of the tumour suppressor gene LKB1, provide an
important step towards a detailed understanding of the complex
molecular events that promote carcinogenesis.
Results
Identification of the LKB1 core promoter
As a first step towards localizing important control regions that
activate LKB1 gene expression, we cloned the region flanking the
59-end of the coding sequence in front of a luciferase reporter gene.
The reporter plasmid containing the nucleotide sequence from
21536 to +727 relative to the LKB1 transcriptionstart site (referred
to as LKB1 Pro I), was active following transient transfection of
‘‘444’’ cells. As a second step, six 200 bp 59-deletion mutants
(referred to as LKB1 Pro II–VII) were constructed (Figure 1A) and
luciferaseactivitywas measured(Figure 1B).Consecutivedeletion of
the sequence from 21536 to 2345 resulted in minimal changes of
the promoter activity. Stronger decreases were only observed when
the LKB1 Pro III construct was further deleted, indicating that
important cis-regulatory elements are located in the area down-
stream of nucleotide 2345. The deletion from 2345 to 2186
(LKB1 Pro IV) reduced luciferase activity by 50%. The next shorter
deletion construct (LKB1 Pro V) showed only 12.5% of the LKB1
ProIIIactivity.Removingthetranscriptionalstartsite [3]byfurther
truncation of LKB1 Pro V, decreased luciferase activity to a level
similar to that obtained by transfection with the empty vector. The
fact that the residual 550 bp of the 59-untranslated region (59-UTR)
within LKB1 Pro VI could not activate reporter gene expression
alone, indicates that important regulatory elements are located
upstream of nucleotide +182.
Interestingly, data-base analysis using the human genome
browser of the Encyclopedia of DNA Elements (ENCODE) [28]
revealed that the area between nucleotide 2345 and the trans-
criptional start site coincides with a previously described DNaseI
hypersensitive region (Figure 1A). This has been identified by a
genome-wide chromatin analysis in different cell types including
HepG2 cells, normal human epidermal keratinocytes and normal
human lung fibroblasts [29]. Since the sequence within the LKB1
Pro III construct is crucial for reporter gene transcription and co-
localize with a nucleosomal structure that is highly accessible to
exogenously added DNaseI, favours the notion that the LKB1 core
promoter is located downstream of nucleotide 2345.
Deletion mutant analysis of the LKB1 promoter identifies
regulatory regions
In order to localize critical cis-regulatoryelementswithintheLKB1
core promoter more precisely, we constructed a series of 20 bp
deletion mutants of LKB1 Pro III (Figure 1C). These constructs (III/
0–8; IV/0–6 and V/0–5) are schematically outlined in Figure 1D
(left). After transient transfection of ‘‘444’’ cells with these 24 different
deletion constructs, including those used in the previous assay (LKB1
Pro III/0, IV/0, V/0 and VI/0, see Figure1A), luciferase activity was
measured (Figure 1D, right). While sequence deletions from 2345 to
2246 did not affect promoter activity, further truncation of III/5 to
III/6 reduced luciferase activity to 65% of the wild-type promoter.
The next drop in luciferase activity was observed between III/7 and
III/8 when nucleotides 2206 to 2187 were deleted. III/8 and IV/0
reached only 57% of the LKB1 Pro III/0 reporter activity and it even
dropped to 22% after removing nucleotides 2166 to 2147.
Interestingly, all three sequence deletions between nucleotides
2345 and 2147 that decreased LKB1 promoter activity exhibit
homology to consensus sequences for CCAAT boxes [30] (Figure1D,
left). Another critical deletion removes a sequence homologous to a
transcription factor consensus site was located between nucleotides
228 and 28 (Figure 1D, left). It contains a potential binding site for
FOXO transcription factors [22] and reduced luciferase activity of
the V/0 construct by 65%. The residual activity was similar to that of
the promoterless vector (Figure 1D, right).
Likewise, deletions of each CCAAT box and the predicted
FOXO binding site also decreased luciferase activity when HPV-
negative C33a cells were transfected, although the extent of
reduction was slightly different (Figure S1). Two deletions were
found to have effects on promoter activity, which were apparently
cell type specific. While ‘‘444’’ cells showed an additional drop in
activity between IV/3 and IV/4, activity in C33a cells decreased
between IV/4 and IV/5.
Substitution mutant analyses identify LKB1 promoter
elements critical for activated transcription
In the course of our 20 bp deletion mutation analysis, we found
strong promoter activity within the area downstream of nucleotide
2345 of the LKB1 promoter which is apparently mediated by
CCAAT boxes and a FOXO binding site (Figure 1D, left).
Interestingly, phylogenetic footprint analysis revealed high homol-
ogy of these elements between human, rhesus, mouse, rat and
zebrafish, indicating that the sequences required for the binding of
activators to the promoter have been conserved, despite having
evolved under heterogeneous constraints (Figure 2A). In order to
confirm the relevance of these regions in a context in which the
promoter length remains unchanged, we generated 21 substitution
mutants where 10 bp sequences between positions 2345 to +72
were systematically altered by inserting a NheI restriction site
(Figure 2B, referred to as III/1–8, IV/0–6 and V/0–5). After
transient transfection of ‘‘444’’ and C33a cells with the mutant
promoter constructs, luciferase activity was measured (Figure 2C,
‘‘444’’; Figure S1, C33a) and the result was compared to the
phylogenetic footprint analysis of the 2345 to +72 sequence
(Figure 2A). The first potential CCAAT box, whose deletion had
reduced promoter activity by 35%, was not disrupted by the
corresponding substitution mutation III/5. Mutation of the second
CCAAT box (III/7), substituting nucleotides 2196 to 2187,
caused only a minimal decrease of 16% in luciferase activity in
‘‘444’’ cells. Consistent with the previous analysis (Figure 1D), in
which deletion of the site caused only 12% reduction in activity,
this suggests a less important function of the second CCAAT box.
The first clear reduction that reduced luciferase activity in both
cell lines investigated was generated by mutation of the sequence
from 2157 to 2148, containing the third potential CCAAT box.
The corresponding construct (IV/0) showed only 34% of the wild-
type activity in ‘‘444’’ cells. Another critical element was disrupted
by the V/0 mutation, which reduced wild type activity to 46% in
‘‘444’’ cells. This element contains the potential FOXO binding
site and did also affect promoter activity in the deletion analysis
(Figure 1D, right). In addition, we found two other mutations
downstream of the FOXO site that reduced promoter activity by
greater than 50% in both cell lines. One was disrupting the area
around the transcription start site from +3t o+12 where the
corresponding construct (V/1) showed 49% of the wild-type
activity in ‘‘444’’ cells. The other mutation was disrupting an
Transcriptional Regulation of LKB1
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element was located within the 59-UTR between nucleotides +43
to +52. The corresponding mutant (V/3) showed only 10% of the
wild-type activity (Figure 2C, marked in red) and lacks apparent
similarities to consensus sites for known transcription factors.
The transcription factor Sp1 binds to a regulatory
element downstream of the transcriptional start site
To get insight which transcription factor can bind to this
element within the 59-UTR, electrophoretic mobility shift assays
(EMSA) were performed. When nuclear extracts of ‘‘444’’ and
HepG2 cells were incubated with a DNA probe comprising this
LKB1 downstream element (LKB1 DSE), a single protein-DNA
complex was observed (Figure 3B, lanes 1–2). To characterize the
nature of the corresponding binding factor, we used an excess of
different unlabeled competitor oligonucleotides containing con-
sensus sequences for known transcription factors (Figure 3A).
While the intensity of the band was not affected by the addition of
competitor containing AP-1, AP-2, Oct-1, CRE, SRE and E2F
sites (Figure 3B, lanes 3–4 and 6–9, respectively), binding was
completely inhibited by an excess of a Sp1 consensus site
containing oligonucleotide (lane 5). Furthermore, complex forma-
tion was competed by a molar excess of the wild-type oligo, but not
by the corresponding mutant oligo harbouring the same mutations
as the substitution mutant V/3 (Figure 3C, lanes 3 and 4,
respectively). Finally, addition of an antibody against the
transcription factor Sp1 specifically retarded the complex, while
the addition of an antibody against the closely related Sp3 did not
(Figure 3C, lanes 5 and 6). Although the LKB1 DSE within the 59-
UTR differs from the classical GC box at two nucleotide positions,
a similar binding site for Sp1 has been identified previously [31].
These results suggest that the ubiquitously expressed transcription
factor Sp1 is involved in LKB1 regulation.
Binding of NF-Y to three CCAAT boxes within the LKB1
promoter
Based on the results of the LKB1 promoter mutant analysis,
oligonucleotides containing the potential CCAAT boxes were also
Figure 1. Deletion-mutant analysis of the LKB1 promoter. (A) Regions of high mammalian and vertebrate sequence conservation in the 59-
flanking region of the LKB1 coding sequence are aligned to DNase I hypersensitive sites (DNAse HS) in HepG2, normal human epidermal
keratinocytes (NHEK) and normal human lung fibroblasts (NHLF) and to LKB1 200 bp deletion mutants (LKB1 Pro I–VII) extending from nucleotide
position 21536 to +727 relative to the transcription start site (modified from the UCSC genome browser at http://genome.ucsc.edu/ENCODE/). (B)
Luciferase activity of transiently transfected ‘‘444’’ cells with 200 bp deletion constructs (I–VII) of the LKB1 promoter. (C) 20 bp deletion mutants of
the LKB1 promoter Pro III fragment, starting from nucleotide 2345 to +727 (III–V) were constructed, digested by the restriction enzymes SacI and
XhoI and separated in a 1% agarose gel. The transcriptional start site (TSS) as well as the 59-untranslated region (59-UTR) is indicated. (D) Comparison
of luciferase activity of transiently transfected ‘‘444’’ cells with LKB1 promoter 20 bp deletion constructs (right) and predicted cis-regulatory elements
(left). The positions of the potential CCAAT boxes I–III as well as the forkhead box are indicated. Luciferase activity of all deletion constructs (relative
light units normalized against renilla luciferase activity) is expressed as the percentage of the signal obtained with the plasmid containing the LKB1
promoter region downstream of nucleotide 2345 (LKB1 Pro III). All assays were performed three times in quadruplicate. The error bars denote mean
6 standard deviation.
doi:10.1371/journal.pone.0032590.g001
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HepG2 cells were incubated with three different radiolabeled
double-stranded oligonucleotides (LKB1 CCAAT-1, 2 and 3,
Figure 4B). Both extracts generated one predominant protein-
DNA complex with all three oligonucleotides (‘‘complex B’’). In
addition, both cell lines formed a second complex (complex D)
only with the LKB1 CCAAT-3 oligo. Another complex (‘‘complex
C’’) was only formed in HepG2 cells when oligos CCAAT-2 and 3
were examined. Specificity was confirmed by the absence of
complex formation when a 500-fold molar excess of the unlabeled
wild-type oligo was included (lanes 3, 9 and 15, respectively). In
contrast, competition with a mutant oligo had no effect on
complex formation (lanes 4, 10 and 16).
The heterotrimeric transcription factor NF-Y has been described
to bind CCAAT boxes [30]. To test whether these protein-DNA
complexes contain NF-Y proteins, antibodyincubationexperiments
Figure 2. Substitution mutant analysis of the LKB1 promoter. Match of phylogenetic footprint with substitution mutant analysis of the LKB1
promoter region ranging from nucleotide position 2345 to +75. (A) Mammalian base-wise conservation (blue and red bars) is displayed together
with sequence alignments of different species, predicted transcription factor (TF)-binding sites (red boxes) and positions of mutations within the
corresponding substitution mutants of the LKB1 promoter reporter constructs. Conserved sequences (‘‘Mammal Cons’’) are indicated in blue, non-
conserved sequences in red. The height of the corresponding bars represents the degree of conservation. Mutations which reduce reporter activity in
the substitution mutant analysis by more than 50% are highlighted in a light red background, while mutations without influence on reporter activity
are coloured in a light blue background. Display of alignments and mammalian conservation were modified from the UCSC genome browser (see
Fig. 1). The positions of the potential CCAAT/Forkhead/Sp1 boxes are indicated as red rectangles. (B) Substitution mutants of the LKB1 promoter Pro
II fragment, encompassing nucleotides 2549 to +727, were constructed by introducing a 10 bp mutation, comprising a NheI restriction site, within
the area of 2345 to +75 by PCR and religation with the respective deletion mutant. The presence of the mutation within the LKB1 promoter was
monitored by agarose gel electrophoresis following restriction enzyme digestion with SacI and NheI. (C) Luciferase activity of transiently transfected
‘‘444’’ cells with LKB1 promoter 10 bp substitution mutants reveals a critical role of four cis-acting elements regulating LKB1 transcription (red bars).
Activity of substitution mutants (relative light units normalized against renilla luciferase activity) is expressed as the percentage of the signal obtained
with the plasmid containing the LKB1 wild-type promoter (LKB1 Pro II, 2549 to +727). Each bar represents the means 6 standard deviation of three
independent experiments made in quadruplicate.
doi:10.1371/journal.pone.0032590.g002
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alpha subunit of NF-Y altered the mobility of the uppermost
complex (‘‘complex A’’; lanes 5, 11 and 17, respectively) in
comparison to the addition of a non-specific antibody (lanes 6, 12
and 18). Notably, the HepG2 specific ‘‘complex C’’ was not shifted
by the NF-YA antibody, indicating that an additional protein,
which is not presentin‘‘444’’cellscanbindto this element.Dueto a
different metabolic state, it is possible that the HepG2 specific
complex may be necessary for the high transcriptional steady-state
level of the LKB1 gene in liver cells [3].
Interaction between FOXO proteins and the LKB1
promoter
Since mutation of a potential forkhead box transcription factor
binding site within the LKB1 promoter significantly reduced
promoter activity (Figure 1D), we assumed that FOXO proteins
Figure 4. Binding of NF-Y transcription factor to CCAAT boxes within the LKB1 promoter.
32P-labeled double-stranded oligonucleotides
harbouring the CCAAT boxes (their positions relative to the transcriptional start site, TSS, are indicated) (A) were incubated with 2 mg of nuclear
extracts from ‘‘444’’ cells (lanes 1, 7 and 13) or from HepG2 cells (lanes 2–6, 8–12, and 14–18) and separated in a 7% polyacrylamide gel (B). Formation
of sequence specific protein complexes was confirmed by competition with unlabeled oligos. Specific bands (indicated by arrows B, C and D) were
competed by a 500-fold molar excess of wild-type oligo (WT; lanes 3, 9 and 15) but not by the same excess of mutant oligo (MUT; lanes 4, 10 and 16,
respectively). Protein complexes containing the transcription factor NF-Y (arrow A) were further retarded by addition of an antibody against NF-Ya
(NFY; lanes 5, 11 and 17) but not by the addition of the same amount of normal goat IgG (IgG; lanes 6, 12 and 18).
doi:10.1371/journal.pone.0032590.g004
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radiolabeled double-stranded oligonucleotide, containing the
potential FOXO binding site of the LKB1 promoter was carried
out (Figure 5). Purified GST-tagged FOXO3 protein (lanes 2–6),
but not GST interacted specifically with the oligo (lane 1) resulting
in the formation of a single DNA-protein complex (Figure 5A).
Sequence specificity of the complex was further confirmed by
oligonucleotide competition and antibody incubation experiments.
Here, complex formation was both effectively competed by an
excess of unlabeled wild-type but not with mutant oligo and
supershifted by the addition of a GST specific antibody.
In further experiments, nuclear extracts from ‘‘444’’ cells after
transfection with either expression plasmids encoding different
FOXO proteins or siRNA directed against all FOXO factors in
non-transfected cells were incubated with the probe in the presence
of an excess of mutated competitor (Figure 5B). Complex formation
was inhibited in cells treated with siRNA against FOXO proteins
(lane 1). In contrast, ectopic expression of FOXO4 (lane 3) or
mutant FOXO4 A3 (lane 4) that is constantly localized within the
nucleus [32], as well as FOXO3 (lane 7) increased formation of the
FOXO containing complexes when compared to transfections with
the corresponding empty vectors (indicated a ‘‘V’’, see lanes 2 and
6). Moreover, an antibody against FOXO4 altered the mobility of
the FOXO4 containing complex (FOXO4 supershift, SS; lane 5)
and an antibody against FOXO3 disrupted the FOXO3 containing
complex (lane 8). In addition, incubation of the oligonucleotide with
extracts from HepG2 cells resulted in the formation of a different
complex (lane 10). It is unlikely that this complex is formed by
another FOXO member, since none of the used cell lines expressed
FOXO1 or FOXO6 (data not shown). Since HepG2 cells express
the liver specific transcription factor FOXA2, also known as HNF-
3b [33], it can be assumed that the observed protein-DNA complex
may contain this factor. After ectopic expression of FOXA2 in
‘‘444’’ cells, known to lack this factor endogenously, complex
formation with similar mobility could be discerned (lane 9),
indicating that also other forkhead box transcription factors can
bind to this element in a tissue specific manner. However, as
deducedfromEMSAanalysis,FOXO3and FOXO4seemtobethe
key player in LKB1 gene regulation (see below).
Chromatin immunoprecipitation demonstrates binding
of NFY, Sp1 and FOXO proteins to the endogenous LKB1
promoter
In order to examine whether NF-Y, Sp1 and the FOXO
proteins also bind to the LKB1 promoter in vivo, chromatin
immunoprecipitation (ChIP) assays were performed (Figure 6). All
antibodies against NF-YA, Sp1, FOXO3 and FOXO4 specifically
enriched the region containing the LKB1 core promoter in
comparison to a non-specific antibody. In contrast, no enrichment
was observed for the LKB1 coding sequence. Taken together, the
ChIP analysis confirms the interaction between NF-Y, FOXO3
and FOXO4 with the endogenous LKB1 promoter and further
supports a critical role of these factors in LKB1 gene expression.
Ectopic expression of Sp1, NF-Y and the FOXO
transcription factors FOXO3 and FOXO4 activates the
LKB1 promoter
In order to show a function of these factors in LKB1 regulation,
co-transfections with LKB1 luciferase reporter constructs and
Figure 5. Binding of forkhead box transcription factors FOXO3 and FOXO4 to the LKB1 promoter. (A) The
32P-labeled double-stranded
oligonucleotide 59-GGGGAGGGAGGTAAACAAGATGGCGGC-39 containing the 228 to 22 region of the LKB1 core promoter was incubated with either
25 ng of recombinant GST (lane1) or GST-tagged FOXO3 protein (lane 2–6) and separated in a 4% polyacrylamide gel. (B) The same oligonucleotide
as described in (A), but incubated with 4 mg of nuclear extracts from ‘‘444’’ cells (lanes 1–9) or from HepG2 cells (lane 10) in the presence of a 500-fold
molar excess of the mutant unlabeled oligo 59-GGGGAGGGAGGTAGCCAAGATGGCGGC-39. Protein complexes containing the transcription factors
FOXO3, FOXO4 and FOXA2 are indicated by arrows. Cells were transfected with either siRNA against the FOXO family members (lane1) or with
expression plasmids encoding FOXO4 (lane 3), mutant FOXO4 A3 (lane 4 and 5), FOXO3 (lane 7 and 8), FOXA2 (lane 9) or with the corresponding
empty vectors (V) (lane 2 and 6). Addition of an antibody against FOXO4 (lane 5) resulted in further retardation of the FOXO4 containing complex
(FOXO4 SS), while addition of the FOXO3 antibody (lane 8) inhibited formation of the FOXO3 complex.
doi:10.1371/journal.pone.0032590.g005
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were performed (Figure 7). Transient transfection of Sp1
significantly increased luciferase activity of the wild-type promoter
when compared with the empty vector. In contrast, no induction
could be discerned when Sp1 was co-transfected with the
substitution construct (LKB1 Pro V/3) where the Sp1 binding
site was mutated (Figure 7A). Ectopic expression of all three NF-Y
subunits also activated the LKB1 wild-type promoter, while the
deletion construct that lacks all three CCAAT boxes (LKB1 Pro
IV/1) could not be induced (Figure 7B). Finally, FOXO proteins
also induced reporter gene expression in a sequence specific
manner, since the respective mutant LKB1 Pro Mut V/0 was not
activated to the same extent after co-transfection with different
FOXO expression plasmids (Figure 7C). Although FOXO3
expression significantly increased luciferase activity of the wild-
type promoter, induction after FOXO4 transfection was only
marginal. One reason for this could be a post-translational
modification of the FOXO4 protein. As described above,
transcriptional activity of all FOXO proteins is negatively
regulated by the protein kinase B (PKB) through direct
phosphorylation of three amino acid side chains [24,25]. When
mutants of the two FOXO proteins, which lack these PKB
phosphorylation sites (FOXO3 A3 and FOXO4 A3) were
transfected, LKB1 reporter gene expression was activated even
more efficiently (Figure 7C). These results demonstrate that Sp1,
NF-Y as well as FOXO3 and FOXO4 have the ability to activate
the LKB1 promoter through interaction with their corresponding
binding sites.
Knockdown of NF-Y and FOXO transcription factors
inhibits LKB1 gene expression
To further investigate the role of NF-Y and the FOXO proteins
in activating endogenous LKB1 gene transcription, siRNA
knockdown experiments were performed. While delivery of siRNA
against Sp1 resulted in massive cell death, treatment of ‘‘444’’,
C33a and IMR-90 cells with NF-YA siRNA significantly
diminished endogenous mRNA levels of the alpha subunit of the
NF-Y complex (Figure 8A). In contrast, mRNA levels of NF-YB
and GAPDH, which were used as internal controls, were not
affected. Consistent with the previous experiments, LKB1 mRNA
and protein levels were strongly reduced after the NF-YA
knockdown, indicating that NF-Y is essential for LKB1 gene
expression (Figure 8A and B). Moreover, siRNA knockdown of
FOXO3 and FOXO4 also decreased LKB1 expression, both on
mRNA and protein level (Figure 9). Furthermore, phosphorylation
of AMPKa, the main substrate of LKB1 was also significantly
reduced under these conditions (Figure 8 and 9), indicating that
individual knockdown of both NF-YA or the two FOXO proteins
FOXO3 and FOXO4 not only diminished LKB1 gene expression,
but also interfered with the LKB1-AMPK signalling pathway by
reducing AMPK activation.
Discussion
In the present study we performed a systematic analysis of the
LKB1 promoter. Using extensive deletion and mutant analyses,
we identified multiple control elements important for LKB1 gene
transcription. Three of these elements contained CCAAT boxes
and were recognized by the heterotrimeric transcription factor
NF-Y [30]. Another evolutionary highly conserved element
contained a binding site for forkhead box transcription factors
and interacted specifically with the transcription factors FOXO3
and FOXO4 [22].
Besides these factors, whose binding sites were all located
upstream of the transcription start site, we found another critical
element within the 59-untranslated region (59-UTR). It has been
identified as a Sp1 site that was apparently essential for promoter
activity in the transient transfection assays (Figure 2). Furthermore,
ectopic expression of Sp1 significantly increased LKB1 promoter
activity (Figure 7A).
Although Sp1 was longtime considered to be a house-keeping
transcription factor, the protein is involved in glucose metabolism
where Sp1 binding to the acetyl-CoA carboxylase promoter
increased transcription in adipocytes [34]. Moreover, Sp1 is also
regulated by energy deprivation [35] and plays a role in insulin
signaling. However, to which extent Sp1 contributes to endoge-
nous LKB1 expression still remains to be elucidated, since siRNA
knockdown of Sp1 caused massive cell death in all cell lines
investigated. Remarkably, the Sp1 element was not sufficient to
activate reporter gene expression alone (Figure 1). It is therefore
tempting to speculate that the Sp1 site located within the 59-UTR
apparently may cooperate with control elements located upstream
of the transcription start site. Indeed, a precedential case has been
described for the major histocompatibility complex class II-
associated invariant chain, where Sp1 and NF-Y cooperatively
activate the gene in cancer cell lines [36]. Consistent with this
notion is the fact that siRNA knockdown of the alpha subunit of
NF-Y but also of FOXO transcription factors greatly reduced
endogenous LKB1 expression (Figure 8 and 9). Moreover,
phosphorylation of the alpha subunit of AMPK, the main
downstream effector of LKB1, was also diminished under these
conditions. This indicates that these proteins, in conjunction with
Sp1, are not only indispensible for efficient transcription of the
gene, but also affect the activation of downstream targets in the
LKB1 signaling pathway.
Although we have shown that Sp1, NF-Y and the FOXO
transcription factors are necessary for effective LKB1 gene
transcription in our cell systems, there also exists the possibility
that other functionally important cis-regulatory elements and trans-
acting factors exist that influence LKB1 promoter activity in a
tissue-specific manner. First, deletion and substitution mutations at
other locations had cell line specific but significant effects on
promoter activity (Comparison Figure 1 and Figure S1). Second,
other cell line specific DNA-binding activities were detected by
EMSA. In detail, the liver specific transcription factor FOXA2
(also named HNF-3b) was also able to bind to the FOXO
recognition site in the LKB1 promoter (Figure 5). Furthermore,
additional studies have shown that different members of this huge
Figure 6. Chromatin immunoprecipitation (ChIP) analysis of
NF-Y, FOXO3 and FOXO4 binding at the LKB1 promoter.
Enrichment of PCR products specific for the LKB1 promoter region
(upper panel) in comparison to PCR products specific for the LKB1
coding region encompassing exon 4–5 (lower panel). PCR products
were amplified from sonified DNA after ChIP, subsequently run on a 1%
agarose gel and stained with ethidium bromide. As a positive control
(Input), 1/10 of the starting material was used for PCR. Protein-DNA
complexes were either incubated with non-specific goat IgG (negative
control) or with antibodies against the transcription factors NFY-a, Sp1
(sc-14027 X), FOXO3 or FOXO4. The figure shows a representative of
three independent experiments.
doi:10.1371/journal.pone.0032590.g006
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motifs [37,38]. It therefore remains possible that beside FOXO3
and FOXO4, also other members of this transcription factors
family may regulate LKB1 gene expression in a cell type specific
manner. Since the expression pattern of each family member
ranges from restricted to a single tissue to nearly ubiquitous, it also
seems possible that these factors are either redundant or
indispensable in certain tissues. Further experiments will be
needed to dissect the role of other forkhead box transcription
factors in the regulation of the LKB1 promoter in various cell
types and in correlation with their metabolic state.
Notably, the activity of FOXO transcription factors is not only
controlled by tissue specific expression, but also by a variety of
posttranslational modification, including phosphorylation, acety-
lation and ubiquitination [23]. For instance, phosphorylation of
FOXO3 by AMPK leads to the activation of its transcriptional
activity [39]. Having shown that LKB1 transcription is induced by
FOXO3 and since AMPK is a direct target of LKB1 [12,13], our
analysis suggests that the expression of LKB1 might be stimulated
by AMPK via a positive regulatory feedback loop, allowing a
cross-talk between these enzymes to counterbalance each other in
the coordination of anabolic and catabolic activities.
How could LKB1 react to changes of the external milieu? Here,
phosphorylation of three conserved serine/threonine residues
within FOXO proteins by the proto-oncogene PKB may play an
important role [24,25]. This specific phosphorylation is mainly
triggered by growth factors like insulin or the insulin-like growth
factors and results in the inhibition of FOXO factors due to their
export from the nucleus [32]. Notably, in our experiments we
could show that PKB phosphorylation site deficient mutants of
FOXO3 and FOXO4 were even more potent in inducing LKB1
promoter activity than the wild type forms (Figure 7C). It therefore
seems possible that the insulin-phosphatidylinositol 3-kinase –
PKB signalling pathway negatively regulates LKB1 expression
through inactivation of FOXO transcription factors. Although
further experiments will be needed to prove this assumption, there
are other reports supporting the existence of this functional link.
Recently it was shown that LKB1 transcription was down-
regulated upon induction of the serum and glucocorticoid-
inducible kinase 1 (SGK-1) [40]. SGK-1, like PKB, belongs to
the same family of protein kinases [41], is a downstream effector of
the phosphatidylinositol 3-kinase pathway and is also able to
phosphorylate FOXO transcription factors at the same residues
like PKB [42]. Since there is now considerable evidence that
insulin and the insulin-like growth factors play important roles in
neoplasia [43], it will be one of the future goals to elucidate
whether these hormones are involved in the down regulation of
the LKB1 tumour suppressor in certain tumour entities.
Materials and Methods
Antibodies
All antibodies were obtained from commercial suppliers and
used without further purification. Mouse monoclonal anti-LKB1
(ab15095) was purchased from Abcam, rabbit monoclonal anti-
phospho-AMPKa Thr172 (2535/40H9) was purchased from Cell
Signaling Technology, goat polyclonal anti-NF-YA (sc-7712 X),
rabbit polyclonal anti-FOXO3 (sc-11351 X), goat polyclonal anti-
FOXO4 (sc-5221 X), rabbit polyclonal anti-Sp1 (sc-59 X), rabbit
polyclonal anti-Sp1 (sc-14027 X), rabbit polyclonal anti-Sp3 (sc-
644 X), rabbit polyclonal anti glutathione-S-transferase (GST) (sc-
459) and normal goat IgG (sc-2028) were from Santa Cruz
Biotechnology. Horseradish peroxidase-conjugated secondary
antibodies, polyclonal goat anti-rabbit IgG (W4011) and anti-
mouse IgG (W4012) were from Promega.
Cell Culture
The HPV-negative cervical carcinoma cell line C33a and
hepatocellular carcinoma cells HepG2 were obtained from American
Type Culture Collection. The normal fibroblastline IMR-90 and the
non-tumourigenic somatic cell hybrids made between HeLa cells and
IMR-90 (referred to as ‘‘444’’) were kindly provided by E. Stanbridge
[44,45]. All cells were maintained in Dulbecco modified Eagle
medium (DMEM) (Sigma) supplemented with 10% (v/v) of foetal
bovine serum (Gibco Life Technologies, Paisley, United Kingdom),
penicillin (final concentration: 100 U/ml, Gibco) and streptomycin
(final concentration: 0.1 mg/ml, Gibco).
Plasmids
The plasmids pJET1.2 (Fermentas), pGL3-Basic (Promega),
pRL-null (Promega), pRL-TK (Promega) and pcDNA3 (Invitro-
gen) have been purchased from commercial suppliers.
Figure 7. NF-Y, Sp1 and FOXO transcription factors activate transcription from the LKB1 promoter. Luciferase reporter assays in C33a
cells after over-expression of Sp1 (A), NF-Y (B) and FOXO transcription factors (C). Reporter activity of LKB1 wild-type promoter is indicated in dark
grey, while reporter activity of constructs lacking the corresponding transcription factor binding site is indicated in light grey. Luciferase activity
(relative light units normalized to renilla luciferase activity) is expressed as the percentage of the signal obtained from co-transfection of 100 ngo f
the plasmid containing the LKB1 wild-type promoter (LKB1 Pro II, 2549 to +727) together with 150 ng of the empty expression vector (CTR). Instead
of the empty vector 150 ng of the corresponding transcription factor expression plasmid have been co-transfected. In the case of NF-Y 50 ng of
plasmids encoding each subunit NF-Ya, NFY-b and NF-Yc were transfected together. Each bar represents the means 6 standard deviation of three
independent experiments.
doi:10.1371/journal.pone.0032590.g007
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passing nucleotides 21536 to +1321 relative to the transcription
start site was amplified by PCR using 200 nM of forward (59-
CACCCTGCCTAATGTCCCTA-39) and reverse (59-GAGTC-
CAGCACCTCCTTCAC-39) primers, 2 ng/ml of genomic DNA
from ‘‘444’’ cells as a template and 0.05 U/ml of PfuUltra HF
DNA polymerase (Stratagene) in a final volume of 25 ml PfuUltra
reaction buffer containing 0.1 mM dNTP’s, 4% of dimethylsulf-
oxide and 2% of formamide. The PCR-product was purified,
cloned into the pJET1.2 plasmid using the CloneJET PCR
Cloning Kit (Fermentas) according to the manufacturer’s instruc-
tions and verified by DNA sequencing. The LKB1 promoter
(position 21536 to +727) was then subcloned into the SmaI site
of the pGL3-Basic luciferase reporter vector by PCR amplification
using the same forward primer and the reverse primer (59-
GCCCACGGACAAGTATGAAC-39) with Phusion High-Fideli-
ty DNA-polymerase (Finnzymes) according to the manufacturer’s
instructions. Deletion mutants were generated by PCR using
primers listed in Table S1 and inserted into the SmaI site of the
pGL3-Basic plasmid. Substitution mutants of the LKB1 promoter
were derived from the deletion mutants by inserting a second PCR
product expanding from 2549 to the deletion end point, using an
upstream primer containing a SacI site and the 2549 sequence
and downstream primers containing a NheI site and the sequence
adjacent to the respective deletion end point (Table S1).
Figure 8. NF-Ya transcription factor is required for LKB1 gene
expression. Knockdown of endogenous NF-Ya by siRNA inhibits LKB1
expression in ‘‘444’’, C33a and IMR-90 cells. Cells were transfected either
with scrambled siRNA (Ctr) or with a siRNA targeting NF-Ya (NF-YA).
Total RNA was purified and mRNA levels of NF-YA, NF-YB, LKB1 and
GAPDH were analysed by RT-PCR using ethidium bromide staining (A).
Equal amounts of total protein (5 mg) were separated by SDS-PAGE and
analysed by western blotting using antibodies against LKB1, phospho-
AMPK (Thr172) and actin (B). The data shown is representative of three
independent experiments.
doi:10.1371/journal.pone.0032590.g008
Figure 9. FOXO transcription factors are required for LKB1
gene expression. Knockdown of endogenous FOXO3 and FOXO4 in
‘‘444’’, C33a and IMR-90 cells. Cells were transfected either with
scrambled siRNA (Ctr) or with a siRNA targeting all FOXO family
members (FOXO). Total RNA was purified and relative mRNA levels of
FOXO3, FOXO4, LKB1 and GAPDH were analysed by RT-PCR using
ethidium bromide staining (A). Equal amounts of total protein (5 mg)
were separated by SDS-PAGE and analysed by western blotting using
antibodies against FOXO3, LKB1 phospho-AMPK (Thr172) and actin (B).
The data shown is representative of three independent experiments.
doi:10.1371/journal.pone.0032590.g009
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constructed by inserting a minimal TATA box of the adenovirus
type 2 major late promoter [46] between the BglII and SalI sites of
the pRL-null plasmid.
Eukaryotic expression plasmids were generated by inserting PCR
amplified full length cDNA of NF-YA (NM_002505.4), NF-YB
(NM_006166), NF-YC (NM_014223.4), FOXO3 (BC058662) and
FOXO4 (BC106761) into the EcoRV site of the pcDNA3 vector.
Primers used for PCR amplification are listed in Table S1. FOXO3
A3 was created by mutating the three Akt/PKB phosphorylation
sites T32, S253 and S315 to A and FOXO4 A3 has been generated
by site directed mutagenesis of amino acid residues T32, S197 and
S262 to A using primers listed in Table S1.
All plasmids used in transient transfections were purified with
the QIAGEN Plasmid Maxi Kit (Qiagen) and verified by
sequencing prior to transfections.
Luciferase Assays
One day before transfection, C33a and ‘‘444’’ cells were plated
at a density of 2.5610
4/well on a white Nunclon F-96-well plate
(Nunc, Roskilde, Danmark). For the deletion- and substitution
mutant analysis, cells were transfected with 250 ng/well of LKB1-
promoter pGL3 firefly luciferase reporter and 25 ng/well of pRL-
TK renilla luciferase plasmid for normalization using 0.9 ml/well
of Lipofectamine 2000 (Invitrogen) for C33a cells and 1.2 ml/well
for ‘‘444’’ cells. 48 h after transfection, cells were lysed, firefly
luciferase activity was analysed and normalized to renilla luciferase
activity using the dual-luciferase reporter assay system (Promega)
according to the manufacturer’s instructions. For co-expression of
transcription factors and LKB1-luciferase reporters, cells were
transfected with 100 ng/well of LKB1-promoter driven pGL3
firefly luciferase reporters, 0.5 ng/well of pRL-TATA normalisa-
tion plasmid and 150 ng/well of the corresponding expression
plasmid. All experiments were performed at least 3 times in
quadruplicates. A one-way analysis of variance (ANOVA) using
the GraphPad PRISMH program Version 5.0 followed by a
Newman-Keuls post-hoc test was performed for statistical analysis
of the results shown in Figure 1 and 2, and a two-way ANOVA
followed by Bonferroni analysis was performed for statistical
analysis of the results shown in Figure 7. Differences with a p
value,0.05 were considered statistically significant.
Electrophoretic mobility shift assay (EMSA)
200 ng of annealed synthetic oligonucleotide probes were end-
labeled with 6000 Ci/mmol [c-
32P]ATP (Perkin Elmer, Bosten,
USA) by 10 U of T4 polynucleotide kinase (New England Biolabs)
in a final reaction volume of 10 ml for 30 min at 37uC and purified
from a 15% non-denaturing polyacrylamide gel. Approximately
0.2 ng (10–15000 cpm) of the probe was incubated together with
either 25 ng of full length GST-tagged FOXO3 protein (Abnova,
Taipei, Taiwan) or 2–4 mg of nuclear cell extracts for 30 min at
25uC in a final volume of 20 ml binding buffer containing 10%
glycerol, 12 mM HEPES, pH 7.9, 4 mM Tris-HCl, pH 7.9,
60 mM KCl, 1 mM dithiothreitol, 0.6 mg/ml bovine serum
albumin, 0.5 mg of poly(dI-dC) (Sigma) and competitor as
indicated. For supershift assays, 2 mg of the corresponding
antibody were added after 30 min and incubation was continued
for 1 h at 4uC. Subsequently the binding reaction was separated
on a 5.5–7% polyacrylamide gel in 1X TB 90 mM Tris, 90 mM
boric acid).
Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed as described previously [47].
Briefly, 1610
7 of ‘‘444’’ cells were cross-linked with 1%
formaldehyde for 10 min. The reaction was stopped by the
addition of 0.125 mM glycine. Subsequently, cells were washed
with phosphate-buffered saline (PBS) and lysed in ChIP-lysis buffer
(5 mM HEPES pH 8, 85 mM KCl, 0.5% (v/v) Nonidet P-40,
supplemented with 1 mM DTT, 5 mM NaF, 0.1 mM Na3VO4
and ‘‘Complete protease inhibitors’’ (Roche). Lysates were
centrifuged to remove debris and resuspended in ChIP-buffer
(20 mM Tris pH 8, 1.2 mM EDTA, 200 mM NaCl, 0.01% SDS,
1.1% Triton X-100) supplemented with 1 mM DTT, 5 mM NaF,
0.1 mM Na3VO4 and ‘‘Complete protease inhibitors’’(Roche).
Then chromatin was sonicated to shear DNA to an average size of
500 bp, insoluble debris was removed by centrifugation and lysates
(equivalent to 25 mg of DNA) were precleared adding 40 mlo f
protein A/protein G-agarose mixture (Roche) blocked with 40 mg
of sheared salmon sperm DNA (Eppendorf) for 2 h at 4uCi na
total volume of 500 ml ChIP-dilution buffer (16.7 mM Tris pH 8,
167 mM NaCl, 1.2 mM EDTA, 1.1% (v/v) Triton X-100 and
0.01% (v/v) SDS). After centrifugation, supernatants were
incubated with 10 mg of the corresponding antibody for 14 h
and protein-DNA complexes were precipitated for 3 h with 40 ml
of protein A/protein G-agarose mixture. After extensive washing,
the immunocomplexes were eluted in 250 ml of 0.1 M NaHCO3
containing 1% (v/v) SDS and cross-links were reversed by adding
NaCl to a final concentration of 200 mM and vigorous mixing at
65uC for 14 h. After protein digestion with proteinase K (New
England Biolabs), DNA was recovered by phenol-chloroform
extraction and ethanol precipitation and analyzed by semiquan-
titative PCR using the forward primer (59-GTGACCTAC-
GACCCCCTTC-39) and the reverse primer (59-GCTGAC-
GATTGGAGCGTTTG-39) to amplify the LKB1 promoter
region. Primers used for amplification of the LKB1 coding region
encompassing Exon 4–5 were: forward (59-TCAGCTGATT-
GACGGCCTGGA-39) and reverse (59-CCAGCCGACCA-
GATGTCCAC-39).
RNA Interference
Small interfering RNA (siRNA) targeting NF-YA mRNA [48]
(sense strand, 59-GUCCAGACCCUCCAGGUAG-dTdT-39; an-
tisense strand, 59- CUACCUGGAGGGUCUGGAC-dTdT-39)o r
mRNAs of all FOXO family members [49] (sense strand, 59-
AGGAUAAGGGCGACAGCAA-dTdT-39; antisense strand, 59-
UUGCUGUCGCCCUUAUCCU-dTdT-39) and non-targeting
control [50] (DNA target sequence, 59-AACAGTCGCGTTTGC-
GACTGG-39) were purchased from Qiagen. Cells were transfect-
ed using the HiPerfect reagent (Qiagen) according to the
manufacturer’s instruction. For transfection-complex formation,
0.4 nmol of siRNA were mixed with 20 ml HiPerfect in 100 mlo f
serum free DMEM. After 10 min of incubation, C33a and ‘‘444’’
cells were seeded at a density of 5610
5/6 cm plate, IMR-90 at a
density of 7.5610
5/6 cm plate in 4 ml of normal growth medium
and 100 ml of the transfection-complex were added dropwise to
the cell-suspension, leading to a final concentration of 100 nM
siRNA in the culture medium. 48 h after transfection, cells were
splitted and an identical second transfection was performed. 96 h
after the first transfection, cells were lysed as described previously
[30] and cytoplasmic RNA was isolated using the RNeasy Kit
(Qiagen). cDNA was obtained from reverse transcription of 1 mg
of total RNA using 10 ng/ml of p(dN)6 random primers (Roche)
and SuperScript II reverse transcriptase (Invitrogen) in a final
volume of 20 ml according to the manufacturer’s instructions. 1 ml
of cDNA was subsequently used for PCRs using Platinum Taq
DNA polymerase (Invitrogen). All PCRs were monitored within
the linear range, which has been determined for each reaction
individually. PCR condidions for each reaction, including primers,
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listed in Table S1.
For Western blot analysis, total protein content was determined
according to Bradford [51]. Cell lysates were separated by SDS-
polyacrylamide gel electrophoresis (5 mg total protein per lane) on
a 10% separating gel and transferred onto a PVDF-membrane
(Millipore) using a TE 77 semi-dry transfer unit (Amersham
Bioscience). Membranes were then blocked overnight at 4uC,
using 5% of milk powder in TBST (0.15 M NaCl, 10 mM Tris,
0.05% (v/v) Tween 20, pH 8.0). Proteins of interest were
visualized using the antibodies described above and the enhanced
chemoluminescence substrate Plus-ECL (PerkinElmer).
Supporting Information
Figure S1 Deletion and substitution-mutant analysis of
the LKB1 promoter. (A) Comparison of luciferase activity of
transiently transfected C33a cells with LKB1 promoter 20 bp
deletion constructs (right) and predicted cis-regulatory elements
(left). The positions of the potential CCAAT boxes I–III as well as
the forkhead box are indicated. Luciferase activity of all deletion
constructs (relative light units normalized against renilla luciferase
activity) is expressed as the percentage of the signal obtained with
the plasmid containing the LKB1 promoter region downstream of
nucleotide 2345 (LKB1 Pro III). (B) Luciferase activity of
transiently transfected C33a cells with LKB1 promoter 10 bp
substitution mutants reveals a critical role of four cis-acting
elements regulating LKB1 transcription (dark grey bars). Activity
of substitution mutants (relative light units normalized against
renilla luciferase activity) is expressed as the percentage of the
signal obtained with the plasmid containing the LKB1 wild-type
promoter (LKB1 Pro II, 2549 to +727). Each bar represents the
means 6 standard deviation of three independent experiments
made in quadruplicate.
(TIF)
Table S1 Primer list. Sequences of primers used for PCR-
amplification of LKB1 promoter fragments, full length open
reading frames (ORF) of indicated transcription factors, site-
directed mutagenesis of FOXO3 and FOXO4 ORFs and cDNA
of indicated mRNAs after reverse transcription (RT-PCR). For
RT-PCR experiments the annealing temperature, the amplicon
size as well as the number of conducted cycles is indicated.
(DOC)
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